Markets open

Novartis AG

NVS · NYSE

Sep 2026upcoming

Next quarter

Consensus is $2.24 EPS for Sep 2026 across 5 estimates, ranging $2.20 to $2.28.

NVS Jun 2026

Reported Jul 21, 2026

Beat 9.55%

EPS estimate: $2.20
EPS actual: $2.41
Revenue estimate: —
Revenue actual: —
1-day move: -0.51%

Call highlights have not been generated for this quarter.

Symbol: NVS
Type: Stock
Sector: Health Care
Industry: Biotechnology: Pharmaceutical Preparations
Country: Europe
Exchange: NYSE

is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide.Reimagine medicine with us: Visit us at https://www.novartis.

Key Issues

Bullish view

FDA approval of Pluvicto in combination with an androgen receptor pathway inhibitor expands the eligible population to patients with PSMA-positive metastatic hormone-sensitive prostate cancer, supporting a broader commercial opportunity.

Bearish view

The approval alone does not establish sales, uptake or earnings impact, and the stock declined during the reported period despite the regulatory development.